Scientists Identify Immune Cell "Conductors" That Help the Body Fight Cancer

Researchers at the Cancer Research UK Manchester Institute, part of the University of Manchester, have identified a little-understood type of immune cell that could become a new target for cancer immunotherapy. The cells, known as activated dendritic cells, play a crucial role in initiating and sustaining the body's immune attack against tumors.

The findings have been accepted for publication in the journal Immunity and are currently available as a preprint on the SSRN server.

Until now, scientists have struggled to determine the precise role of activated dendritic cells in cancer because there were no tools capable of studying this specific cell population in isolation.

To overcome this challenge, the researchers developed the first mouse models that allow these cells to be either selectively labeled or completely removed from the body.

The experiments demonstrated that activated dendritic cells are essential for an effective anti-tumor immune response. Without them, T cells—the immune cells responsible for destroying cancer cells—cannot be fully activated or maintain their activity within the tumor.

As a result, the body's ability to naturally control tumor growth is weakened, and the effectiveness of cancer immunotherapy is significantly reduced.

According to the study's first author, Maria Koufaki, current immunotherapy approaches rely on a strong and well-coordinated immune response. However, many patients still fail to benefit sufficiently from these treatments.

The researchers believe that enhancing the activity of activated dendritic cells could improve treatment outcomes and offer new hope for patients whose tumors currently respond poorly to immunotherapy.

Senior author Santiago Zelenay explained that these cells not only initiate the immune attack against cancer but also help sustain it within the tumor microenvironment. This discovery could pave the way for the development of more effective immunotherapies.

Although much work remains, the researchers say the new experimental models may help explain why immunotherapy is highly effective for some patients while providing little benefit for others, ultimately supporting the development of more personalized cancer treatments.